Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma
Annie Xiao(City of Hope), Azra Borogovac(University of Oklahoma Health Sciences Center), Tanya Siddiqi(City Of Hope National Medical Center), Geoffrey Shouse(City Of Hope National Medical Center), Steven T. Rosen(Unknown), James Godfrey(City of Hope), Alex F. Herrera(City of Hope), Sanjeet Dadwal(City Of Hope National Medical Center), Avyakta Kallam(City Of Hope National Medical Center), John H. Baird(City Of Hope National Medical Center), Matthew Mei(City of Hope), Alexey V. Danilov(City of Hope), Stacy Pak(City Of Hope National Medical Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Tycel Phillips(City of Hope), Lu Chen(City of Hope), Elizabeth Budde(City of Hope), Brian Lee(City Of Hope National Medical Center)
Cited by 3
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657